TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
TP53 has been proved to be associated with cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastat...
Main Authors: | Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, Chunwei Xu, Wenxian Wang, Guoqiang Wang, Shangli Cai, Jing Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-06-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641830183X |
Similar Items
-
TP53 structural variants in metastatic prostatic carcinoma.
by: Deepika Sirohi, et al.
Published: (2019-01-01) -
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
by: Comin-Anduix Begonya, et al.
Published: (2009-05-01) -
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.
by: Begoña Comin-Anduix, et al.
Published: (2010-09-01) -
Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
by: Dong, Y., et al.
Published: (2022) -
Potential therapeutic targets for oral cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70.
by: Saurabh Bundela, et al.
Published: (2014-01-01)